NCT02037503.

Study name	Effect of oral ketamine treatment on suicidal ideation and drug resistant major depression, a clinical and fMRI study
Methods	In a double‐blind, placebo‐controlled trial, patients admitted to the emergency department after a suicide attempt will be randomised into two groups: one will be given a daily subanaesthetic dose of oral ketamine, while the second group will receive a daily dose of placebo. Participants will be followed up for 21 days. Some of the participants will also undergo functional MRI scans before and after the first ketamine intake Allocation: randomised Endpoint classification: efficacy study Intervention model: parallel assignment Masking: double‐blind (participant, investigator, outcomes assessor) Primary purpose: treatment
Participants	Inclusion criteria Suicidal ideation group: Any person admitted to the emergency room department after a suicide attempt, defined as requiring medical intervention ‐ not just a psychiatrist (surgical or pharmacological treatment but also the need for observation) The need for medical intervention will be defined by the ER ED physician Ages 18‐65 For the depression group Diagnosed with major depression according to DSM VI Ongoing depression (according to DSM criteria) despite treatment with at least two antidepressants in adequate dosages and for longer than three weeks. Ages 18‐65 Exclusion criteria for all groups Psychotic state instate in the examination Diagnosis of schizophrenia/schizoaffective disorder Drug or alcohol abuse as is revealed in by blood/urine tests Patient in which, according to the examiner, there is primary or secondary gain Patient, which, at the time of his admission, is without any pharmacological treatment
Interventions	Ketamine versus saline
Outcomes	Primary outcome measures: Resolution of suicidal ideation. Time frame: within 3 weeks of enrolment
Starting date	January 2014
Contact information
Notes	NCT02037503